SRC and hepatocellular carcinoma: Dasatinib is second generation tyrosine kinase inhibitor that downregulates various tyrosine kinases containing BCR‐ABL1 and kinases of SRC family, and it inhibits the growth of cancer cells (Zhang et al., 2020), including hepatocellular carcinoma cells (Chang & Wang, 2013; Liu et al., 2021).